Category Label

Client Announcements

Contract Extension With Major UK Retailer

  •   14 November 2023

RNS Number : 2855T

Kanabo Group PLC

14 November 2023


A picture containing text, clipart Description automatically generated


14 November 2023


Kanabo Group Plc

("Kanabo", the "Group" or the "Company")


Contract Extension With Major UK Retailer


Kanabo Group plc (LSE: KNB), the patient-focused provider of digital health services and specialist medicines, including medicinal cannabis, is pleased to announce that it has extended an existing contract with a leading United Kingdom ("UK") retail business, a provider of health and beauty retail and e-pharmacy services.


The GP Service - acquired by Kanabo in 2022 - originally partnered with the retailer in 2019. The contract extension will see Kanabo, through its integrated online telehealth platform The GP Service, continue to provide the retailer with video consultation and prescription services, which patients can access remotely and then collect through the Group's network of over 4,000 UK pharmacies for a further 12 months.  


This contract extension will enable Kanabo to continue to offer its online consultation services to an expanded patient base, affording patients faster and easier access to medical professionals.



Avihu Tamir, Chief Executive Officer of Kanabo, commented:


"I am delighted that we have secured an extension of this prestigious contract for Kanabo. The continuation of our relationship with this retailer will help us strengthen our position as a key player in digital health services and also provide accessible care to patients. We look forward to continuing to work with them over the next 12 months, and to enabling greater access to medical professionals and healthcare services for customers."




Kanabo Group plc

Avihu Tamir, Chief Executive Officer

Assaf Vardimon, Chief Financial Officer

Ian Mattioli, Non-Executive Chair of the Board


via Vigo Consulting

+44 (0)20 7390 0230

Peterhouse Capital Limited (Financial Adviser and Broker)

Eran Zucker/Lucy Williams/Charles Goodfellow


+44 (0)20 7469 0930

Vigo Consulting (Financial Public Relations/Investor Relations)

Jeremy Garcia / Fiona Hetherington / Verity Snow

 +44 (0)20 7390 0230


About Kanabo Group plc

Kanabo Group plc (LSE:KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.


Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat It - an online clinic focused on chronic pain management providing patients with secondary care.


With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider, offering telehealth consultations, prescriptions, alongside the delivery of tailored treatments.


The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.


At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visitwww.kanabogroup.comfor more information.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.